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ABSTRACT
Diabetes results from an inadequate mass of functional b cells, due to either b cell loss caused by
autoimmune destruction (type I diabetes) or b cell failure in response to insulin resistance (type II
diabetes). Elucidating the mechanisms that regulate b cell mass may be key to developing new
techniques that foster b cell regeneration as a cellular therapy to treat diabetes. While previous studies
concluded that cyclin D2 is required for postnatal b cell self-renewal in mice, it is not clear if cyclin D2 is
sufficient to drive b cell self-renewal. Using transgenic mice that overexpress cyclin D2 specifically in b
cells, we show that cyclin D2 overexpression increases b cell self-renewal post-weaning and results in
increased b cell mass. b cells that overexpress cyclin D2 are responsive to glucose stimulation, suggesting
they are functionally mature. b cells that overexpress cyclin D2 demonstrate an enhanced regenerative
capacity after injury induced by streptozotocin toxicity. To understand if cyclin D2 overexpression is
sufficient to drive b cell self-renewal, we generated a novel mouse model where cyclin D2 is only
expressed in b cells of cyclin D2¡/¡ mice. Transgenic overexpression of cyclin D2 in cyclin D2¡/¡ b cells was
sufficient to restore b cell mass, maintain normoglycaemia, and improve regenerative capacity when
compared with cyclin D2¡/¡ littermates. Taken together, our results indicate that cyclin D2 is sufficient to
regulate b cell self-renewal and that manipulation of its expression could be used to enhance b cell
regeneration.
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Introduction
Diabetes results from an inadequate mass of functional b cells,
due to either b cell loss caused by autoimmune destruction
(type I diabetes) or b cell failure in response to insulin resis-
tance (type II diabetes).1-3 It may be possible to supplement b
cell mass as a cellular therapy by stimulating the self-renewal of
pre-existing b cells, by differentiating b cells from multipotent
progenitor cells, or by stimulating transdifferentiation from
other cell types.4 Self-renewal of pre-existing b cells is the pre-
dominant mechanism to expand endogenous postnatal b cell
mass in rodents.5 In humans, b cell mass expansion is primarily
driven by b cell self-renewal during childhood.6 Although b cell
self-renewal drops to very low levels in adulthood, it may be
possible to exploit the pathways that regulate b cell self-renewal
to drive therapeutic b cell expansion. Thus, understanding the
processes that regulates b cell self-renewal may provide novel
insights into approaches to expand b cell mass and move the
field toward development of novel regenerative therapies for
diabetic patients.
b cell self-renewal is dependent on and governed by the pre-
cise control of the cell cycle. Entry into the G1 phase of the cell
cycle is initiated by D-type cyclins binding to and activating
cyclin-dependent kinases. Cyclin D2 is the major D-type cyclin
expressed in b cells, and multiple studies have shown its critical
requirement for postnatal b cell mass expansion.7-10 However,
because these studies did not knockout cyclin D2 specifically in
b cells, there was a possibility that unidentified cell types that
may compensate for b cell insufficiency by contributing to new
b cell formation could also be restricted by the absence of cyclin
D2. Evidence for the existence of multipotent progenitor cells in
the adult pancreas after severe injury supports the possibility
that cyclin D2 maybe required in other compartments of the
pancreas that contribute to new b cell formation.11 In addition,
overexpression of a stable species of cyclin D2 (T280A) in adult
animals increased b cell survival but did not enhance self-
renewal, suggesting that extending the half-life of cyclin D2 is
not sufficient to enhance b cell mass through self-renewal.12
While the cyclin D2 T280A model illuminated a novel role for
cyclin D2 in b cell survival, the analogous phosphorylated form
of cyclin D2 has never been detected in b cells, such that the
T280A model may not be reflective of how wildtype cyclin D2
may affect b cell self-renewal. Overexpression of wildtype cyclin
D2 may have different effects on b cell self-renewal and
survival.
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To test if the overexpression of wildtype cyclin D2 could
stimulate b cell self-renewal, we generated a “knock-in”
transgenic mouse that specifically overexpressed cyclin D2
in b cells. We measured a 2-fold increase in cyclin D2
expression in the knock-in b cells, which resulted in an
increased b cell mass. b cell-specific overexpression of cyclin
D2 extended the ability of postnatal b cells to self-renew
post-weaning and enhanced their regenerative capacity in
response to injury. To discern if cyclin D2-mediated b cell
self-renewal was sufficient to maintain normoglycemia, we
bred the b cell-specific cyclin D2 knock-in mice with the
global cyclin D2¡/¡ mice. Re-expression of cyclin D2 in
cyclin D2¡/¡ b cells restored deficits in cyclin D2¡/¡ b cells
mass, re-established the capacity of cyclin D2¡/¡ b cells to
respond to glucose challenge, and restored the regenerative
capacity relative to cyclin D2¡/¡ littermate mice. These
results establish that cyclin D2 is sufficient to drive postna-
tal b cell self-renewal and can enhance the regenerative
capacity of b cells.
Results
Targeted overexpression of cyclin D2 results in a 2-fold
increase in cyclin D2 protein in b cells
Although mice expressing a stable form of cyclin D2 (T280A)
revealed a novel role for cyclin D2 in b cell survival, it is not
known if the overexpression of native cyclin D2 can specifically
drive b cell self-renewal. We generated a transgenic mouse
model where cre-recombinase expressed in insulin cells
(RIP-cre) drove the overexpression of cyclin D2 and labeled all
b cells with a GFP fluorescent lineage trace marker (referred to
herein as KI, Fig. 1A). Immunohistochemistry for the GFP pro-
tein confirmed efficient cre-mediated recombination by co-
expression of GFP and loss of dTomato in insulin-expressing b
cells (Fig. 1B). Next, we measured the expression of cyclin D2
protein in the WT and KI mice. We and others have reported
that the expression of cyclin D2 declines in adult b cells, with a
limited number of cells expressing low levels of cyclin D2.7,8
Immunohistochemistry confirmed limited expression in
Figure 1. b cell specific overexpression of cyclin D2 increases cyclin D2 protein levels. (A) Schematic of the alleles used to create RIP-Cre;cycD2;ROSA26mT/mG mice (KI
mice). Black triangles indicate loxP sites. (B) Representative immunofluorescence staining for insulin or dTomato (red), GFP (green), and DAPI (blue) showing efficient Cre
recombinase-mediated recombination in KI b cells. (C) Representative immunofluorescence staining for of cyclin D2 (red) and insulin (green) in WT and KI pancreatic sec-
tions. (D) Western blot (left panel) and densitometric quantification of cyclin D2 levels (right panel) in isolated islets from WT and KI mice. Data shown as mean § SD of 3
independent experiments.  P<0.01, compared with WT mice.
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wildtype mice, but revealed brighter cyclin D2 expression in an
increased number of b cells in the KI mice (Fig. 1C). We used
western blot analysis to quantify the abundance of cyclin D2 in
islets isolated from 6-week-old mice. Densitometric analysis
determined a 2-fold increase in cyclin D2 expression in KI islets
compared with islets from WT littermates (Fig. 1 D). These
results suggested that the cyclin D2 knock-in transgene was
able to specifically drive the overexpression of cyclin D2 in b
cells.
Overexpression of cyclin D2 promotes b cell self-renewal
post-weaning and results in expanded b cell mass
Perinatal pancreatic remodeling includes a brief window of
high b cell self-renewal, which declines by weaning at P21. We
previously reported that cyclin D2-null (cycD2¡/¡) mice were
born with b cell mass similar to controls at birth, but the loss of
cyclin D2 limited b cell self-renewal and resulted in decreased b
cell mass as early as 7 d after birth.7 To identify whether cyclin
D2 overexpression could enhance postnatal pancreatic b cell
self-renewal, we used immunohistochemistry to quantify the
proportion of Ki67C b cells in WT and KI mice. We noted a
2.5-fold increase in the number of Ki67C b cells in 3-week-old
KI mice in comparison to WT, while no difference was seen in
the 3 months cohort (Fig. 2A-B). To understand if increased
post-weaning self-renewal could result in b cell mass expan-
sion, we measured b cell mass in KI and WT mice at 3 weeks
and 3 months of age. At 3 weeks of age, there was a minor
increase in b cell mass in the KI pancreas when compared with
WT littermates, which was not statistically significant (Fig. 2C).
This suggests that overexpression of cyclin D2 in the perinatal
remodeling period does not drive self-renewal to expand b cell
mass. Quantification of b cell mass at 3 months revealed a
more than 2-fold increase of b cell mass in KI mice compared
with WT mice (Fig. 2C). Next, we wanted to investigate if over-
expression of cyclin D2 increased b cell survival. We quantified
b cell apoptosis by TUNEL assay. Rare TUNEL positive b cells
were identified, and the ratio of TUNELC b cells were compara-
ble between KI and WT b cells at both 3 weeks and 3 months
(data not shown). Taken together, this data suggests that while
overexpression of cyclin D2 during the perinatal remodeling
period does not increase b cell mass, it may be effective in driv-
ing b cell self-renewal to expand b cell mass post-weaning.
To define whether cyclin D2-mediated islet hyperplasia
affected glucose metabolism, we measured glucose tolerance,
insulin tolerance, and insulin secretion in 3-month-old KI and
WT mice. KI mice displayed a mild improvement in glucose
tolerance coupled with increased insulin sensitivity when com-
pared with WT littermates, but differences in the glucose toler-
ance test or insulin tolerance test were not statistically
significant (Fig. 3A-B). This suggested that while there was an
increase in b cell mass, insulin sensitivity was not dysregulated.
It has been suggested that increased levels of b cell self-renewal
may be indicative of a less mature functional state, and thereby
lead to decreases in insulin secretion and b cell function.13 To
understand if overexpression of cyclin D2 affected islet func-
tion, we measured insulin secretion in response to physiologic
concentrations of glucose by glucose stimulated insulin secre-
tion assay. We measured insulin secretion in response to basal
and high concentrations of glucose in islets isolated from 3-
month old WT and KI mice. We did not detect any differences
in response to glucose challenge, suggesting that KI islets were
functionally mature (Fig. 3C). These results indicate that cyclin
D2-overexpressing KI islets are functionally mature and able to
maintain normal glucose homeostasis.
Beta cell specific overexpression of cyclin D2 extends
regenerative capacity into advanced age
Our previous work has illustrated epigenetic mechanisms that
restrict the ability of aged b cells to self-renew in response to
metabolic demand for insulin.14-18 Because overexpression of
cyclin D2 extended the ability of b cells to self-renew, we inves-
tigated if cyclin D2 overexpression could enhance b cell regen-
eration after b cell injury in aged animals. We used a single
dose of streptozotocin (90 mg/kg) to induce b cell death and
evaluated the regenerative capacity of KI b cells in young
(6 weeks old) and old (8 months old) mice. Immunohistochem-
ical analysis of b cells from young mice showed that KI mice
had an increased incidence of large islets when compared with
WT mice, and a higher proportion of b cells expressed Ki67
after STZ administration (Fig. 4A). Quantification of Ki67C
insulin cells revealed a 2-fold increase in b cell self-renewal in
young animals (Fig. 4B). In the old mice, immunohistochemi-
cal analysis of KI b cells revealed a 3-fold increase in Ki67C
expression in the KI b cells after STZ administration (Fig. 4C-
D). While there was a marked increase in self-renewal in the
old KI b cells, it is important to note that the proportion of
Ki67C b cells in the old KI group was 50% lower than the young
group. This suggests that while overexpression of cyclin D2
does enhance the regenerative capacity of old b cells, age-
related restrictions that limit beta cell self-renewal are sus-
tained. We also measured similar increases in b cell self-
renewal and increased b cell mass in old KI animals subjected
to a high fat diet (data not shown). Taken together, these data
revealed that cyclin D2 overexpression enhances the regenera-
tive capacity of b cells in response to b cell injury.
b cell-specific cyclin D2 re-expression restores self-renewal
and the regenerative capacity in the b cells of cyclin D2¡/¡
mice
Our previous work concluded that cyclin D2-mediated b cell
self-renewal is the primary means of b cell mass expansion both
in homeostasis and in response to metabolic demand for
insulin.7,10 At the time, these studies were limited by the use of
the global cyclin D2¡/¡ model and the inability to reconstitute
cyclin D2 expression in cyclin D2¡/¡ b cells. To address these
shortcomings, we crossed KI mice with cyclin D2¡/¡ mice to
restore cyclin D2 expression in specifically in b cells (referred to
herein as KIKO). There were no differences in the body mass
and pancreas mass between WT, KI, and KIKO animals (data
not shown). We used immunohistochemistry to evaluate islet
architecture of the KIKO mouse. When we compared KIKO
islets to the both wildtype and cyclin D2¡/¡ islets, we found that
KIKO mice displayed similar islets size and b cell mass to WT
mice (Fig. 5A). We quantified b cell mass in WT, cyclin D2¡/¡,
and KIKO animals at 3 months old. While the cyclin D2¡/¡ b
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cell mass was considerably decreased in comparison to WT ani-
mals, reconstituting cyclin D2 expression in cyclin D2¡/¡ insulin
cells resulted in a restoration of b cell mass (Fig. 5B). After con-
cluding that reconstituting cycD2 expression can restore b cell
mass in cyclin D2¡/¡ animals, we evaluated the ability of KIKO
b cells to maintain glucose homeostasis. Consistent with previ-
ous findings, cyclin D2¡/¡ mice were glucose intolerant, but
reconstituting cyclin D2 expression in the KIKO mice completely
restored glucose clearance comparable to WT littermates
(Fig. 5C).7,8,10 We next examined if reconstitution of cyclin D2
expression could enhance b cell regeneration in the cyclin D2¡/¡
pancreas after STZ injury. We administered a single dose of STZ
(90 mg/kg) to induce partial b cell loss and measured b cell
regeneration by quantification of Ki67C b cells after 7 d. While
the cyclin D2¡/¡ mice showed a 4-fold decrease in b cell regen-
eration, reconstitution of cyclin D2 expression in b cells restored
b cell regeneration in the KIKO mice (Fig. 5D-E). Taken
together, these experiments suggest that overexpression of cyclin
D2 specifically in the b cell compartment is sufficient to restore
b cell function, mass, and regenerative capacity in the cyclin
D2¡/¡ background.
Discussion
An adequate and functional b cell mass is required to maintain
glucose homeostasis. Increasing numbers of patients in need of
insulin replacement therapy is driving a demand to develop
novel therapeutic strategies to expand functional b cell mass.
Figure 2. Overexpression of cyclin D2 increases b cell proliferation and b cell mass. (A) Representative immunofluorescence staining for insulin (green), Ki67 (red), and
DAPI (blue). White arrows indicate InsCKi67C cells. (B) Quantification of the percentage of b cells expressing Ki67 in WT and KI mice at 3 weeks and 3 months of age. (C)
Quantification of b cell mass in WT and KI mice at 3 weeks and 3 months of age. Data shown as mean § SD (nD 3–4 mice per group). P < 0.05, P < 0.01.
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Understanding the mechanisms that drive b cell self-renewal is
the subject of intense investigation. Our work and others have
shown that cyclin D2 is required for postnatal b cell self-
renewal and under conditions of insulin resistance.7,8,10 Ele-
vated cyclin D2 expression and enhanced b cell growth have
been observed in mouse models such as high fat diet treat-
ment,19 partial pancreatectomy,12 glucose infusion,20 or expo-
sure to prolactin and growth hormone,21 indicating that
increased cyclin D2 may be a necessary component of the cell
cycle machinery that mediates b cell reentry into cell cycle.
In this study, we sought to address if cyclin D2 was sufficient
to drive b cell expansion through self-renewal. Our data indi-
cates that while a 2-fold increase in the expression of cyclin D2
does not influence b cell mass expansion during the early
perinatal remodeling period, it increased b cell self-renewal
post-weaning, thereby expanding b cell mass in adulthood. The
phenotype of KI mice resembles the Cdk4R24C transgenic mice,
which expressed a constitutively active form of the cyclin D2
binding partner, Cdk4. Cdk4R24C mice displayed pancreatic
hyperplasia due to abnormal proliferation of b cells by 3 months
of age.22 Conversely, our results were very different from the
transgenic cyclin D2 T280A b cells, where it was reported that
accumulation of the stabilized form of cyclin D2 did not
increase b cell proliferation, but decreased b cell apoptosis and
increased b cell survival, resulting in increased b cell mass and
eventual tumorigenesis.23 Our KI mice did not exhibit signs of
tumorigenesis by 8 months of age, suggesting that the endoge-
nous mechanisms that regulate cyclin D2 turnover are suffi-
cient to control for cell cycle-dependent cyclin D2-mediated
overgrowth of b cell mass.
Elegant experiments quantifying CldU and IdU thymidine
analogs incorporation into b cells illustrated that b cell self-
renewal is restricted by a refractory period that slows self-
renewal under basal conditions. This refractory period is not
Figure 3. Overexpression of cyclin D2 in b cells does not diminish b cell function. (A) Glucose tolerance test was performed in 3-month-old WT and KI mice. (B) Insulin tol-
erance was performed in 3-month-old WT and KI mice. (C) Glucose stimulated insulin secretion was measured in 3-month-old WT and KI mice. nD 4–5 animals per group.
Data shown as mean § SD of 3 independent experiments. P < 0.01.
Figure 4. Overexpression of cyclin D2 enhances b cell replication in old KI mice. (A, B) Representative immunofluorescence staining (A) and quantification (B) for insulin
(green), Ki67 (red), and DAPI (blue) in young (6-week-old) WT and KI mice challenged with a single dose of STZ (90 mg/kg). C, D. Representative immunofluorescence
staining (C) and quantification (D) for insulin (green), Ki67 (red), and DAPI (blue) in old (8-month-old) WT and KI mice challenged with a single dose of STZ (90 mg/kg).
White arrows indicate InsCKi67C cells. Data shown as mean § SD (n D 3–4 mice per group). P < 0.05, P < 0.01.
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static, as the authors demonstrated that it could be foreshort-
ened in response to partial pancreatectomy.24 In our KI model,
b cell self-renewal was enhanced in aged KI mice treated with
STZ. It is possible that sustained expression of cyclin D2 may
foreshorten the replication refractory period to promote b cell
self-renewal and facilitate regeneration after b cell injury. The
mechanisms that regulate the timing of the refractory period
are not entirely clear, but may be dependent on the balance
between pro-proliferative activity of cyclin D2 and cdk4 com-
plexes and anti-proliferative inhibition by p16ink4a.
We and others have previously reported that there is an
age-dependent decline in b cell self-renewal through downre-
gulation of Bmi1, upregulation of Ezh2, and subsequent accu-
mulation of p16Ink4a.16-18 Neither consumption of a high fat
diet, injury by STZ, nor short-term exposure to GLP1 stimu-
lated increase b cell self-renewal in old mice due to a loss of
Ezh2-mediated repression of p16ink4a.14,25 Subsequent studies
revealed that overexpression of Ezh2 was insufficient to repress
p16ink4a expression in old mice, but could be used in combina-
tion with other epigenetic modulators to re-ignite b cell replica-
tion in old animals.18 The KI mouse model seems to bypass this
epigenetic restriction of b cell self-renewal by overwhelming the
stoichiometric balance between cyclin D2 pro-proliferative sig-
nals and p16Ink4a anti-proliferative signals to drive b cell self-
renewal in adulthood.
In the absence of cyclin D2 pro-proliferative signaling, b cells
are unable to self-renew to meet metabolic demand for insulin.
In this study, we determined that expression of cyclin D2
Figure 5. Reconstituting cyclin D2 expression restores b cell mass, function, and regenerative capacity. (A) Representative immunofluorescence staining glucagon (red),
insulin (green) and DAPI (blue) in 6-week-old WT, KO, and KIKO mice. (B) Quantification of b cell mass in 6-week-old WT, KO, and KIKO mice. (C) GTT was performed in 3-
month-old WT, KO, and KIKO mice. (D, E) Representative immunofluorescence staining (F) and quantification (E) for insulin (green), Ki67 (red), and DAPI (blue) in 6-week-
old WT, KO and KIKO mice treated with a single dose of STZ (90 mg/kg). White arrows indicate InsCKi67C cells. Data shown as mean § SD (n D 3 mice per group).  P <
0.05, P < 0.01, P < 0.005.
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exclusively in b cells was sufficient to drive postnatal b cell self-
renewal to establish a functional b cell mass able to maintain
glucose homeostasis. Interestingly, reconstitution of cyclin D2
expression in the cyclin D2¡/¡ mouse did not expand b cell
mass above that of wildtype littermates (Fig. 5D). This could be
interpreted to mean that the expression of cyclin D2 in other
pancreatic compartments may have a minor contribution to
establishing postnatal b cell mass, which is consistent with
other studies in pancreatic injury models.11,26
Our results suggest that cyclin D2 overexpression has the
potential to enhance b cell regeneration. Previous studies using
human islets have concluded overexpression of cdk6 or increas-
ing signals upstream of cyclin D2 in human islets results in the
accumulation of D-type cyclins and re-entry into the cell
cycle.27,28 Taken together, this suggests cyclin D2, or a comple-
mentary cyclin/cdk analog in humans, is a potential target that
can manipulated to promote b cell expansion for the treatment
of diabetes.
Research design and methods
Mouse husbandry
Stop-floxed-Cyclin D2 conditional KI mice that harbor a
mouse cyclin D2 allele encoding mouse cyclin D2 targeted
immediately after a loxP-flanked transcriptional stop sequence
at the ROSA26R locus were generated at Indiana University in
the DBA/2J background. Targeted disruption of the cyclin D2
allele and the RIP-Cre mice have been described previously and
were on a C57BL/6 background.7,29 The Rosa26R-mTmG (JAX
007576) line was obtained from Jackson Laboratory in the
129Sv/J background. All mice used in these experiments were a
mixture of the given backgrounds and were littermates from
the mixture. Mice were kept under a 12-h light/dark circle with
standard diet. All animal protocols were approved by the Chan-
cellor’s Animal Research Committee at the University of Cali-
fornia, Los Angeles.
Western blotting
Islet isolation was performed as described previously.14 Lysates
extracted by tissue extraction buffer (Invitrogen) were resolved
by SDS-PAGE, followed by transferring to polyvinylidene fluo-
ride membrane for immunoblotting. The membranes were
probed with specific antibodies against cyclin D2 (Santa Cruz),
and b-tubulin (Sigma-Aldrich). For densitometric analysis,
protein levels were normalized to the protein levels of house-
keeping gene b-tubulin. The data presented is representative of
3 independent experiments, using islet lysate from different
mice in each independent experiment.
Immunohistochemistry
Immunohistochemistry was performed as described previ-
ously.14 Antibodies used were: guinea pig anti-insulin (1:400;
Dako), mouse anti-Ki67 (1:40; BD Pharmingen), chicken anti-
GFP (1:250; Aves Labs), rabbit anti-cyclin D2(1:3000; Santa
Cruz) antibody and fluorescein- isothiocyanate- or Cy3-conju-
gated secondary antibodies (The Jackson Laboratory). After
mounting with Vectashield (Vector Laboratories), all the slides
were viewed using a Leica DXMRA microscope and images
acquired using Openlab software. The percentage of Ki67C b
cells was determined by counting how many insulinC b cells
were also Ki67C. A minimum of 1500 b cells from 3 different
sections were counted for each animal. The data are expressed
as the average percentage of Ki67C b cells per genotype, n D 3
animals per genotype.
b cell mass
b cell mass was measured as described previously.10 In brief, 4
to 6 sections from each pancreas were stained with anti-insulin
antibody and scanned by a Leica DM6000 microscope. Mon-
tage images were made by ImageJ software. The cross-sectional
areas of pancreas and b cells were determined by ImagePro
software. b cell mass per pancreas was estimated as the product
of the relative cross-sectional area of b cells per total tissue and
the weight of the pancreas and calculated by examining pan-
creata from at least 3 animals for each genotype.
STZ administration
A single dose of 90 mg/kg STZ (Sigma-Aldrich) in citrate buffer
(pH 4.5) was injected intraperitoneally, and pancreata were
harvested for proliferation index analysis after 7 d as described
previously.14
Metabolic analysis
Glucose tolerance testing was performed after overnight
fasting, and blood glucose levels were measured before
intraperitoneal injection of glucose (2 mg dextrose/g body
wt) and 15, 30, 60, and 120 min after injection. Glucose
stimulated insulin secretion experiment was performed after
1 hour equilibration in Kreb’s buffer containing 2.8 mM
glucose. Islets were sequentially incubated in Kreb’s buffer
containing 2.8 mM Glucose and 16.7 mM glucose for
1 hour, respectively. Supernatant was collected to measure
insulin secretion and islets were harvested to lyse in acid
ethanol to extract insulin. Insulin was measured with mouse
insulin ELISA kit (Mercodia).
Statistical analysis
All data were summarized as the means § SD. Mean and SD
values were calculated from at least triplicates of representative
experiments. Comparisons among 2 groups were made with a
2-tailed paired student’s t-test at a p<0.05 significance level.
Comparisons among the 3 groups were made with 1-way Anal-
ysis of Variance (ANOVA), with 2 Bonferroni-adjusted post
hoc pairwise comparisons between KO and the other 2 groups.
Serial blood glucose levels from GTT were analyzed with
repeated measures ANOVA, with Dunnet test to compare over-
all glucose levels in KO to WT and KIKO groups. Statistical
analysis was performed using SAS/STAT© v9.2 software at a
p <0.05 significance level.
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Abbrevations
Glu glucagon
GSIS glucose stimulated insulin secretion
GTT glucose tolerance testing
Ins insulin
ITT insulin tolerance testing
KI knock-in
KO knockout
WT wild type.
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